BFH772 (VEGFR2 inhibitor): Technical Use and Protocol Guidance

What This Product Solves

BFH772 is a potent VEGFR2 signaling pathway inhibitor designed for research applications where precise and selective inhibition of VEGFR2 is required. By targeting VEGFR2 with high affinity (IC50: 3 nM) and showing markedly reduced activity against related receptors and other kinases, BFH772 enables researchers to dissect VEGFR2-mediated angiogenic processes without the confounding effects of broad-spectrum kinase inhibition. This makes it especially suitable for tumor angiogenesis research and studies requiring clear delineation of VEGFR2-dependent mechanisms. However, due to its insolubility in water and narrow selectivity profile, BFH772 is not appropriate for workflows that demand water-soluble inhibitors or those investigating multiple kinase targets simultaneously. For detailed product specifications and supporting documentation, see the BFH772 (VEGFR2 inhibitor) page at APExBIO.

Protocol Parameters

• Assay: VEGFR2 kinase inhibition
  Value: IC50 = 3 nM
  Applicability: Use in in vitro kinase assays or cell-based studies where high VEGFR2 selectivity is required.
  Rationale: Enables confident attribution of observed effects to VEGFR2 pathway modulation.
  Source: Product information
• Assay: Compound solubility for stock preparation
  Value: ≥53.4 mg/mL in DMSO; ≥15.33 mg/mL in ethanol
  Applicability: Prepare concentrated stocks in DMSO or ethanol for subsequent dilution into assay media.
  Rationale: Ensures maximum solubility and accurate dosing in compatible organic solvents; avoid aqueous media due to insolubility.
  Source: Product information
• Assay: Storage and handling
  Value: Store at -20°C (dry, protected from light); avoid long-term storage of solutions
  Applicability: Maintain compound integrity and reproducibility by following cold storage and minimizing freeze-thaw cycles.
  Rationale: Ensures compound stability and consistent experimental results.
  Source: Product information

Workflow Setup and QC Checklist

• Review compatibility of assay system with organic solvents (DMSO or ethanol) before introducing BFH772. For most cell-based and biochemical assays, limit final solvent concentrations to ≤0.1–0.5% to minimize cytotoxicity or assay interference.
• Dissolve BFH772 in DMSO or ethanol at high concentration (e.g., 10–20 mM) to prepare master stocks. Ensure complete dissolution by vortexing and, if needed, brief sonication. Inspect visually to confirm absence of precipitate.
• Aliquot master stocks to avoid repeated freeze-thaw cycles. Store aliquots at -20°C in tightly sealed, light-protected vials.
• Before each use, allow aliquots to equilibrate to room temperature and vortex to resuspend any settled material.
• Document batch numbers, prepare an experimental log of compound dilutions, and retain accompanying certificates of analysis and safety data sheets for quality assurance.
• Validate VEGFR2 inhibition in your system by including positive and negative controls. Monitor for off-target effects, especially when using higher compound concentrations.

For further workflow guidance, see the article BFH772 (VEGFR2 inhibitor): Technical Use and Workflow Guidance, which details practical considerations for solubility and selectivity in assay development. The article BFH772 (VEGFR2 inhibitor): Technical Guidance & Workflow Parameters provides additional insight into optimal scenarios for use and protocol limitations.

Common Failure Modes and Fixes

• Precipitation in aqueous media: If BFH772 precipitates upon dilution, confirm that the final concentration of DMSO or ethanol in the working solution is sufficient to maintain solubility. If precipitation persists, reduce compound concentration or increase solvent percentage (within cell/assay tolerance limits).
• Inconsistent inhibition or variable results: Check for compound degradation due to improper storage or repeated freeze-thaw cycles. Always use freshly thawed aliquots and inspect for changes in color, clarity, or odor.
• Off-target effects at high concentrations: As selectivity decreases at higher inhibitor levels, verify the minimal effective concentration for your assay and monitor for any off-target cellular responses.
• Assay interference from solvent: Ensure that DMSO or ethanol levels are matched across all experimental conditions, including controls, to avoid confounding effects.

Scope and Limitations

• BFH772 is highly selective for VEGFR2 (IC50 = 3 nM) with significantly reduced potency against FLK-1, FLT-1, FLT-4, and other kinases (>40-fold lower efficacy), making it unsuitable for studies seeking broad-spectrum kinase inhibition or multi-target profiling.
• The compound is insoluble in water, restricting its use to assays compatible with DMSO or ethanol as solvents. It is not recommended for applications requiring water-based delivery or high-throughput screening formats that cannot tolerate organic solvents.
• Long-term storage of solutions is discouraged due to potential compound degradation. Always prepare fresh working solutions from powder or frozen stock aliquots.
• All numeric performance parameters and solubility limits are based on manufacturer product data (APExBIO); do not extrapolate beyond provided data without additional validation.

Conclusion

BFH772 (VEGFR2 inhibitor, SKU B6199) provides a robust tool for researchers needing precise and selective inhibition of the VEGFR2 signaling pathway, particularly in angiogenesis and tumor model systems. Its high selectivity and well-defined solubility profile support reproducible, targeted modulation of VEGFR2 activity when organic solvent compatibility is assured. To ensure reliable results, adhere strictly to documented solubility, storage, and workflow parameters, and regularly consult quality control documentation. For complete product details and supporting resources, refer to the BFH772 (VEGFR2 inhibitor) page at APExBIO.